1. Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.
- Author
-
Sethi, Tarsheen K., Kovach, Alexandra E., Grover, Natalie S., Huang, Li-Ching, Lee, Laura A., Rubinstein, Samuel M., Wang, Yang, Morgan, David S., Greer, John P., Park, Steven I., Ann Thompson-Arildsen, Mary, Yenamandra, Ashwini, Vnencak-Jones, Cindy L., and Reddy, Nishitha M.
- Subjects
- *
APOPTOSIS , *CENTRAL nervous system , *PROGRAMMED cell death 1 receptors , *EPSTEIN-Barr virus , *PROTEIN expression - Abstract
Primary central nervous system lymphoma (PCNSL) patients have a poorer prognosis than systemic lymphoma. Gain-of-function MYD88 c.794T > C (p. L265P) mutation and programed cell death-1 (PD-1) pathway alterations are potential targetable pathways. Our study objective was to determine the clinicopathologic correlates of MYD88 mutation and PD-1 alterations in PCNSL and the impact of Epstein–Barr virus (EBV) infection. We studied 53 cases including 13 EBV-associated (EBVpos) PCNSL, 49% harbored MYD88 mutation, none seen in EBVpos PCNSL. MYD88 protein expression did not correlate with MYD88 mutation. T-cell and macrophage infiltration was common. All PD-L1-positive tumors were EBVpos. Two PD-L1 positive tumors showed 9p24.1/PD-L1 locus alterations by Fluorescence In Situ Hybridization. T cells and macrophages expressed PD-1 and/or PD-L1 in 98% and 83% cases, respectively. MYD88 mutation or protein expression and PD-1 or PD-L1 expression did not predict outcome. We hypothesize that EBVpos PCNSL has a distinct activation mechanism, independent of genetic alterations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF